. Author manuscript; available in PMC: 2023 Jan 5.

Published in final edited form as: Cell. 2022 Oct 13;185(21):3857–3876. doi: 10.1016/j.cell.2022.09.023

Table II.

Approved JAK inhibitors

Indication	Drug
Rheumatoid arthritis	Tofacitinib, Baricitinib, Upadacitinib, Filgotinib, Peficitinib
Psoriatic arthritis	Tofacitinib, Upadacitinib
Juvenile arthritis (> 2 yrs)	Tofacitinib
Ankylosing spondyloarthritis	Tofacitinib, Upadacitinib
Ulcerative Colitis	Tofacitinib, Filgotinib,
Atopic Dermatitis	Baricitinib, Upadacitinib, Abrocitinib, Delgocitinib (topical), Ruxolitinib (topical), Oclacitinib (dogs)
Alopecia Areata	Baricitinib
Graft Versus Host Disease	Ruxolitinib
Myeloproliferative neoplasms	Ruxolitinib, Fedratinib, Pacritinib
Covid-19	Baricitinib
Vitiligo	Ruxolitinib (topical)
Plaque Psoriasis	Deucravacitinib